/

Omnicell, Inc.

OC9 GS

OC9 GSOmnicell, Inc.

FIGI: BBG000D6S5V5

46.60

EUR

-1.40

(-2.92%)

Next Earnings

October 31

Held by Insiders

1.56%

Held by Institutions

102.83%

Short % of Float

4.90%

YTD Yield

-46.07%

3Y Yield

-25.00%

Capital Structure

USD

•

in mil. unless spec.

Dec'22

Mar'23

Jun'23

ST Debt

LT Borrowings

567

568

LT Finance Leases

Preferred Equity and Hybrid Capital

- -

Shares Outstanding

Market Capitalization

2,256

2,644

3,330

Working Capital

USD

•

in mil. unless spec.

Dec'22

Mar'23

Jun'23

Total Current Assets

882

935

881

Cash, Cash Equivalents & STI

342

351

411

Accounts Receivable, Net

299

322

274

Inventories

148

141

131

Total Current Liabilities

428

454

370

Payables & Accruals

236

262

193

ST Debt

Deferred Revenue

119

143

125

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years

5 years

1 year

Sales/Revenue/Turnover

15.80%

12.95%

14.49%

Net Income, GAAP

212.78%

29.08%

-92.31%

Free Cash Flow

-92.39%

-173.52%

-90.17%

Total Cash Common Dividend

- -

Total Equity

14.26%

17.47%

-1.48%

Quarterly Revenue

USD

•

in mil. unless spec.

Year

2021

252

273

296

311

1,132

2022

319

331

348

298

1,296

2023

291

299

- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

2021

0.33

0.47

0.67

0.32

1.79

2022

0.19

0.21

0.38

-0.64

0.13

2023

-0.33

0.08

- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

2021

- -

2022

- -

2023

- -

Company Description

CEO: Mr. Randall A. Lipps
Full Time Employees: 3,780
Sector: Healthcare
Industry: Health Information Services
Address: 2625 Augustine Drive Santa Clara CA United States 95054
Website: www.omnicell.com
Business: Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; Omnicell Interface Software that offers interface and integration between its medication-use products or supply products, and a healthcare facility's in-house information management systems; and robotic dispensing systems for handling the stocking and retrieval of boxed medications. It also provides central pharmacy automation solutions; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems. In addition, the company provides single-dose automation solutions that fill and label a variety of patient-specific, single-dose medication blister packaging based on incoming prescriptions; fully automated and semi-automated filling equipment for institutional pharmacies to warrant automated packaging of medications; and medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings. Further, it offers EnlivenHealth Patient Engagement, a web-based nexus of solutions. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Santa Clara, California.

Company Description

CEO: Mr. Randall A. Lipps
Full Time Employees: 3,780
Sector: Healthcare
Industry: Health Information Services
Address: 2625 Augustine Drive Santa Clara CA United States 95054
Website: www.omnicell.com
Business: Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; Omnicell Interface Software that offers interface and integration between its medication-use products or supply products, and a healthcare facility's in-house information management systems; and robotic dispensing systems for handling the stocking and retrieval of boxed medications. It also provides central pharmacy automation solutions; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems. In addition, the company provides single-dose automation solutions that fill and label a variety of patient-specific, single-dose medication blister packaging based on incoming prescriptions; fully automated and semi-automated filling equipment for institutional pharmacies to warrant automated packaging of medications; and medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings. Further, it offers EnlivenHealth Patient Engagement, a web-based nexus of solutions. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Santa Clara, California.

Company News

Dow Jones Newswires
4 months ago
Omnicell Taps Nchacha Etta as CFO
Dow Jones Newswires
4 months ago
Omnicell Appoints Nchacha E. Etta As Executive Vice President And Chief Financial Officer >OMCL
Dow Jones Newswires
5 months ago
Omnicell 1Q Loss/Shr 33c >OMCL

Next Earnings

October 31

Held by Insiders

1.56%

Held by Institutions

102.83%

Short % of Float

4.90%

YTD Yield

-46.07%

3Y Yield

-25.00%

Working Capital

USD

•

in mil. unless spec.

Dec'22

Mar'23

Jun'23

Total Current Assets

882

935

881

Cash, Cash Equivalents & STI

342

351

411

Accounts Receivable, Net

299

322

274

Inventories

148

141

131

Total Current Liabilities

428

454

370

Payables & Accruals

236

262

193

ST Debt

Deferred Revenue

119

143

125

Capital Structure

USD

•

in mil. unless spec.

Dec'22

Mar'23

Jun'23

ST Debt

LT Borrowings

567

568

LT Finance Leases

Preferred Equity and Hybrid Capital

- -

Shares Outstanding

Market Capitalization

2,256

2,644

3,330

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years

5 years

1 year

Sales/Revenue/Turnover

15.80%

12.95%

14.49%

Net Income, GAAP

212.78%

29.08%

-92.31%

Free Cash Flow

-92.39%

-173.52%

-90.17%

Total Cash Common Dividend

- -

Total Equity

14.26%

17.47%

-1.48%

Quarterly Revenue

USD

•

in mil. unless spec.

Year

2021

252

273

296

311

1,132

2022

319

331

348

298

1,296

2023

291

299

- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

2021

- -

2022

- -

2023

- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

2021

0.33

0.47

0.67

0.32

1.79

2022

0.19

0.21

0.38

-0.64

0.13

2023

-0.33

0.08

- -